KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Gross Profit (2016 - 2025)

Historic Gross Profit for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $80.4 million.

  • Neogenomics' Gross Profit rose 743.32% to $80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.2 million, marking a year-over-year increase of 990.48%. This contributed to the annual value of $290.1 million for FY2024, which is 1859.99% up from last year.
  • Neogenomics' Gross Profit amounted to $80.4 million in Q3 2025, which was up 743.32% from $77.3 million recorded in Q2 2025.
  • Neogenomics' 5-year Gross Profit high stood at $80.4 million for Q3 2025, and its period low was $38.2 million during Q1 2022.
  • Moreover, its 5-year median value for Gross Profit was $59.9 million (2023), whereas its average is $60.0 million.
  • Data for Neogenomics' Gross Profit shows a peak YoY increase of 8920.95% (in 2021) and a maximum YoY decrease of 2122.78% (in 2021) over the last 5 years.
  • Over the past 5 years, Neogenomics' Gross Profit (Quarter) stood at $45.3 million in 2021, then grew by 25.56% to $56.8 million in 2022, then increased by 18.94% to $67.6 million in 2023, then increased by 14.31% to $77.3 million in 2024, then increased by 4.13% to $80.4 million in 2025.
  • Its Gross Profit was $80.4 million in Q3 2025, compared to $77.3 million in Q2 2025 and $73.2 million in Q1 2025.